Genitourinary syndrome of the menopause –dawn of a new era?

Climacteric

Volumn 18, Issue , 2015, Pages 13-17

  Panay, N ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Genitourinary syndrome of menopause; GSM; Most bothersome symptom; Quality of life; Vaginal health index; Vulva health index; Vulvovaginal atrophy

Indexed keywords

PRASTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ESTROGEN; LUBRICATING AGENT;

ARTICLE; ATROPHIC VAGINITIS; ATROPHY; DAY TO DAY IMPACT OF VAGINAL AGING QUESTIONNAIRE; DYSPAREUNIA; DYSURIA; ESTROGEN DEFICIENCY; FEMALE; FEMALE GENITAL TRACT PARAMETERS; GENITOURINARY SYNDROME; HUMAN; LOW LEVEL LASER THERAPY; MATURATION; MENOPAUSE; NOCTURIA; NOMENCLATURE; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL AROUSAL DISORDER; URINARY FREQUENCY; URINARY TRACT ATROPHY; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; VAGINA ATROPHY; VAGINA DISCHARGE; VAGINA PH; VAGINA SMEAR; VAGINAL DRYNESS; VAGINAL MATURATION INDEX; VAGINAL PRURITUS; VULVA ATROPHY; VULVA DISEASE; VULVA PRURITUS; DEFICIENCY; FEMALE UROGENITAL DISEASES; GYNECOLOGY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; QUESTIONNAIRE; SYNDROME; URINARY TRACT; VAGINA; VAGINAL DISEASES; VULVA;

ATROPHY; ESTROGENS; FEMALE; FEMALE UROGENITAL DISEASES; GYNECOLOGY; HUMANS; LUBRICANTS; MENOPAUSE; POSTMENOPAUSE; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; SYNDROME; URINARY TRACT; VAGINA; VAGINAL DISEASES; VULVA;

EID: 84973450877     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2015.1070564     Document Type: Article

References (15)

1. Portman D J, G ass M L; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Climacteric 2014; 17: 557-63
2. Nappi R E, P alacios S. I mpact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014; 17: 3-9
3. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA)-results from an international survey. Climacteric 2012; 15: 36-44
4. Nappi R, P alacios S, Panay N, Rabe T, Krychman M, Particco M. Results of the European REVIVE (REal Women’s VIew of Treatment Options for Menopausal Vulvar/Vaginal ChangEs) survey. Presented at the 10th Congress of the European Menopause and Andropause Society, Madrid, May 2015, Abst 254
5. Laumann EO, Paik A, Rosen RC. S exual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537-44
6. Bachmann GA, Notelovitz M, Kelly SJ, et al. Long-term nonhormonal treatment of vaginal dryness. Clin Pract Sex 1992; 8: 12
7. Palacios S. The vulval health index. Personal communication, 2015
8. Erekson EA, Yip SO, Wedderburn TS, et al. The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause 2013; 20: 973-9
9. Huang A J, G regorich S E, Kuppermann M, et al. D ay-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and wellbeing in postmenopausal women. Menopause 2015; 22: 144-54
10. Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, de Villiers TJ, Simon JA. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 2015; 18: 233-40
11. Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010; 13: 509-22
12. NAMS Position Statement. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013; 20: 888-902
13. Gambacciani M, L evancini M, C ervigni M. V aginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. Climacteric 2015; 18: 757-63
14. Labrie F, Archer D F, B ouchard C, et al.; Members of the VVA Prasterone Group. Prasterone has parallel benefi cial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas 2015; 81: 46-56
15. Palacios S, Mejia A, Neyro JL. Treatment of the genitourinary syndrome of menopause. Climacteric 2015; 18 (Suppl 1): 22-8